News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Roche (RHHBY) Wins Battle Over Launch Of Biosimilar Version Of Its Breast Cancer Drug Herceptin


2/7/2014 8:08:21 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

In a major turn of events, the Indian arm of Swiss pharma major Roche, recently sued Bangalore based Biocon and US based generic giant Mylan in Delhi High Court (HC) for launching world's first biosimilar version of its original breast cancer drug Herceptin (trastuzumab) in India. It is understood that the company has also sued the Drug Controller General of India (DCGI) for giving permission for such a launch. Roche has told the court that the drugs of Biocon and Mylan are being misrepresented as 'biosimilar Trastuzumab' and 'biosimilar version of Herceptin' without following the 'due process in accordance with the guidelines on similar biologics' for getting approvals in India.

Help employers find you! Check out all the jobs and post your resume.


comments powered by Disqus
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES